Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rollover study of BIBF 1120 in idiopathic pulmonary fibrosis
NL-OMON34511Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Primary endpoint: Forced vital capacity decline. Started Sep 2010; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON34511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34511.